BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 14529136)

  • 21. Use of histologic margin evaluation to predict recurrence of cutaneous malignant tumors in dogs and cats after surgical excision.
    Scarpa F; Sabattini S; Marconato L; Capitani O; Morini M; Bettini G
    J Am Vet Med Assoc; 2012 May; 240(10):1181-7. PubMed ID: 22559107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcome of dogs with mast cell tumors in the inguinal or perineal region versus other cutaneous locations: 124 cases (1990-2001).
    Sfiligoi G; Rassnick KM; Scarlett JM; Northrup NC; Gieger TL
    J Am Vet Med Assoc; 2005 Apr; 226(8):1368-74. PubMed ID: 15844431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of stage and number of tumours on prognosis of dogs with cutaneous mast cell tumours.
    Murphy S; Sparkes AH; Blunden AS; Brearley MJ; Smith KC
    Vet Rec; 2006 Mar; 158(9):287-91. PubMed ID: 16517820
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Soft tissue sarcomas and mast cell tumours in dogs; clinical behaviour and response to surgery.
    Baker-Gabb M; Hunt GB; France MP
    Aust Vet J; 2003 Dec; 81(12):732-8. PubMed ID: 15080482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of histologic tumor characteristics and size of surgical margins with clinical outcome after surgical removal of cutaneous mast cell tumors in dogs.
    Schultheiss PC; Gardiner DW; Rao S; Olea-Popelka F; Tuohy JL
    J Am Vet Med Assoc; 2011 Jun; 238(11):1464-9. PubMed ID: 21627510
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunohistochemical detection of proliferating cell nuclear antigen and Ki-67 in mast cell tumors from dogs.
    Abadie JJ; Amardeilh MA; Delverdier ME
    J Am Vet Med Assoc; 1999 Dec; 215(11):1629-34. PubMed ID: 14567425
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of tumour depth, tumour location and multiple synchronous masses on the prognosis of canine cutaneous mast cell tumours.
    Kiupel M; Webster JD; Miller RA; Kaneene JB
    J Vet Med A Physiol Pathol Clin Med; 2005 Aug; 52(6):280-6. PubMed ID: 16050909
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase II clinical trial of vinorelbine in dogs with cutaneous mast cell tumors.
    Grant IA; Rodriguez CO; Kent MS; Sfilgoi G; Gordon I; Davis G; Lord L; London CA
    J Vet Intern Med; 2008; 22(2):388-93. PubMed ID: 18312556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cutaneous mast cell tumors in cats: 32 cases (1991-1994).
    Molander-McCrary H; Henry CJ; Potter K; Tyler JW; Buss MS
    J Am Anim Hosp Assoc; 1998; 34(4):281-4. PubMed ID: 9657159
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mast cell tumor destruction by deionized water.
    Grier RL; Di Guardo G; Schaffer CB; Pedrosa B; Myers R; Merkley DF; Thouvenelle M
    Am J Vet Res; 1990 Jul; 51(7):1116-20. PubMed ID: 2117868
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The prognostic value of lymph node metastasis with grade 2 MCTs in dogs: 55 cases (2001-2010).
    Baginski H; Davis G; Bastian RP
    J Am Anim Hosp Assoc; 2014; 50(2):89-95. PubMed ID: 24446400
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Iridium-192 interstitial brachytherapy as adjunctive treatment for canine cutaneous mast cell tumors.
    Northrup NC; Roberts RE; Harrell TW; Allen KL; Howerth EW; Gieger TL
    J Am Anim Hosp Assoc; 2004; 40(4):309-15. PubMed ID: 15238561
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic factors for radiation treatment of mast cell tumor in 85 dogs.
    Turrel JM; Kitchell BE; Miller LM; Théon A
    J Am Vet Med Assoc; 1988 Oct; 193(8):936-40. PubMed ID: 3142828
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs.
    Patnaik AK; Ehler WJ; MacEwen EG
    Vet Pathol; 1984 Sep; 21(5):469-74. PubMed ID: 6435301
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognosis of canine mast cell tumors: a comparison of three methods.
    Simoes JP; Schoning P; Butine M
    Vet Pathol; 1994 Nov; 31(6):637-47. PubMed ID: 7863578
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of scar revision after inadequate primary excision of cutaneous mast cell tumors in 85 dogs (2000-2013).
    Karbe GT; Davis E; Runge JJ; Brown DC; Holt DE
    Vet Surg; 2021 May; 50(4):807-815. PubMed ID: 33666268
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytologic Criteria for Mast Cell Tumor Grading in Dogs With Evaluation of Clinical Outcome.
    Camus MS; Priest HL; Koehler JW; Driskell EA; Rakich PM; Ilha MR; Krimer PM
    Vet Pathol; 2016 Nov; 53(6):1117-1123. PubMed ID: 27034386
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytological lymph node evaluation in dogs with mast cell tumours: association with grade and survival.
    Krick EL; Billings AP; Shofer FS; Watanabe S; Sorenmo KU
    Vet Comp Oncol; 2009 Jun; 7(2):130-8. PubMed ID: 19453367
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of surgical margins required for complete excision of cutaneous mast cell tumors in dogs.
    Simpson AM; Ludwig LL; Newman SJ; Bergman PJ; Hottinger HA; Patnaik AK
    J Am Vet Med Assoc; 2004 Jan; 224(2):236-40. PubMed ID: 14736068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term outcomes of dogs undergoing surgical resection of mast cell tumors and soft tissue sarcomas: A prospective 2-year-long study.
    Milovancev M; Townsend KL; Tuohy JL; Gorman E; Bracha S; Curran KM; Russell DS
    Vet Surg; 2020 Jan; 49(1):96-105. PubMed ID: 31044443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.